Published in Trends Endocrinol Metab on December 03, 2013
Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma. Curr Opin Nephrol Hypertens (2015) 0.87
Transcriptomic signatures of peroxisome proliferator-activated receptor α (PPARα) in different mouse liver models identify novel aspects of its biology. BMC Genomics (2014) 0.76
TNF-α stimulates endothelial palmitic acid transcytosis and promotes insulin resistance. Sci Rep (2017) 0.75
Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1. World J Cardiol (2014) 0.75
Metabolic Regulation of Angiogenesis in Diabetes and Aging. Physiology (Bethesda) (2017) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res (2000) 10.95
Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem (2008) 9.56
Thiazolidinediones. N Engl J Med (2004) 9.42
Nuclear receptors and lipid physiology: opening the X-files. Science (2001) 8.76
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
PPARs and the complex journey to obesity. Nat Med (2004) 7.44
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A (2003) 6.82
Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest (1996) 6.50
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov (2008) 5.78
CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest (2001) 5.72
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 4.88
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A (1998) 4.82
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature (2007) 4.59
Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell (1994) 4.33
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J (1996) 4.11
Muscle-specific Pparg deletion causes insulin resistance. Nat Med (2003) 3.93
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ (2012) 3.82
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia (2012) 3.70
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol (1997) 3.52
Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature (2008) 3.44
Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature (2010) 3.40
Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol (2012) 3.09
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99
Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S A (2006) 2.90
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem (2000) 2.85
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature (2012) 2.83
GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab (2010) 2.75
Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med (2011) 2.74
Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl) (2002) 2.70
An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med (2012) 2.59
A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med (2011) 2.34
Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest (2002) 2.30
Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res (2008) 2.15
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation (2000) 2.15
A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci U S A (1998) 2.12
eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab (2009) 2.04
Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res (1998) 1.97
Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood (2008) 1.93
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A (2009) 1.91
Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest (2008) 1.89
Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology (2005) 1.88
Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J (2009) 1.79
The endothelial cell. Br Med J (1966) 1.75
Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol (1999) 1.72
Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis (2007) 1.72
Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol (2006) 1.68
Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res (2013) 1.68
VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest (2008) 1.68
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest (2008) 1.68
Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res (2009) 1.67
Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010) 1.60
Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest (2011) 1.60
Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad Sci U S A (1996) 1.57
In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol (2007) 1.54
Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol (2000) 1.49
Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev (2013) 1.49
Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab (2008) 1.48
TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J (2006) 1.34
Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation (2010) 1.31
Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol (2011) 1.30
Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta (2011) 1.26
The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-gamma. Mol Endocrinol (2008) 1.23
Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J Neurosci (2008) 1.23
Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood (2010) 1.22
The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci (1996) 1.21
Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab (2009) 1.19
Structure and function of VEGF receptors. IUBMB Life (2009) 1.15
Insulin resistance in genetically obese, hyperglycemic mice. Endocrinology (1971) 1.14
Greater transport efficiencies of the membrane fatty acid transporters FAT/CD36 and FATP4 compared with FABPpm and FATP1 and differential effects on fatty acid esterification and oxidation in rat skeletal muscle. J Biol Chem (2009) 1.13
Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One (2010) 1.09
Mutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1. Proc Natl Acad Sci U S A (2011) 1.09
Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes (2011) 1.05
Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes (2013) 1.03
GPIHBP1 C89F neomutation and hydrophobic C-terminal domain G175R mutation in two pedigrees with severe hyperchylomicronemia. J Clin Endocrinol Metab (2011) 1.02
The msr/apj gene encoding the apelin receptor is an early and specific marker of the venous phenotype in the retinal vasculature. Gene Expr Patterns (2003) 1.00
Endothelial cells of the human microvasculature express epidermal fatty acid-binding protein. Circ Res (1997) 0.99
Translational promise of the apelin--APJ system. Heart (2010) 0.98
Assessing mechanisms of GPIHBP1 and lipoprotein lipase movement across endothelial cells. J Lipid Res (2012) 0.98
Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms. Endocrinology (2010) 0.98
Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood (2013) 0.96
Peroxisome proliferator-activated receptor-γ in capillary endothelia promotes fatty acid uptake by heart during long-term fasting. J Am Heart Assoc (2013) 0.95
Acute hypoxia induces hypertriglyceridemia by decreasing plasma triglyceride clearance in mice. Am J Physiol Endocrinol Metab (2012) 0.94
Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler Thromb Vasc Biol (1997) 0.92
Apelin attenuates UVB-induced edema and inflammation by promoting vessel function. Am J Pathol (2011) 0.91
Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells--brief report. Arterioscler Thromb Vasc Biol (2012) 0.88
CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS One (2012) 0.87
Transport of long-chain fatty acids across the muscular endothelium. Adv Exp Med Biol (1998) 0.83
Heart microvessels and aortic endothelial cells express the 15 kDa heart-type fatty acid-binding proteins. Eur J Cell Biol (1998) 0.79
A Tale of Two Elabela Null Mice. Trends Endocrinol Metab (2017) 0.75